FDA Approves First Quadrivalent, Adjuvanted Flu Vaccine for Older Adults

The U.S. Food and Drug Administration (FDA) has approved a quadrivalent formulation of first-and-only adjuvanted season flu vaccine for adults 65 and older from Seqirus, confirms HCPLive . The Fluad Quadrivalent vaccine employs the same MF59 adjuvant as Seqirus's Fluad medication. A 2019 study in Clinical Infectious Diseases showed that enhanced flu vaccines can better protect older adults, and the MF59-adjuvanted vaccine was one of three study vaccines which induced a stronger immune response than in the standard vaccine cohort. "Adults 65 years and older are at high risk for influenza-related complications each season and it is important to have influenza vaccines to help protect this vulnerable population," stated Seqirus General Manager Anjana Narain. Adults 65 years and older also have had the highest rate of hospitalization in the current flu season.